AR023925A1 - EXTRACT OF TUMOR CELLS MODIFIED BY DUAL HAPTENIZATION AND METHODS OF TREATMENT OR PROTECTION FOR CANCER - Google Patents
EXTRACT OF TUMOR CELLS MODIFIED BY DUAL HAPTENIZATION AND METHODS OF TREATMENT OR PROTECTION FOR CANCERInfo
- Publication number
- AR023925A1 AR023925A1 ARP990106876A ARP990106876A AR023925A1 AR 023925 A1 AR023925 A1 AR 023925A1 AR P990106876 A ARP990106876 A AR P990106876A AR P990106876 A ARP990106876 A AR P990106876A AR 023925 A1 AR023925 A1 AR 023925A1
- Authority
- AR
- Argentina
- Prior art keywords
- tumor cells
- methods
- dual
- cancer
- haptenization
- Prior art date
Links
- 210000004881 tumor cell Anatomy 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000009977 dual effect Effects 0.000 title abstract 2
- 239000000284 extract Substances 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical group NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 abstract 1
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 abstract 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- -1 dinitrophenyl group Chemical group 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 abstract 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Composiciones que comprenden células tumorales haptenizadas dualmente y extractos de las mismas, métodos para preparar las composiciones, vacunas quecomprenden tales células tumorales haptenizadas dobles, y métodos para tratar el cáncer con tales vacunas. En una realizacion específica, células de melanoma yde adenocarcinoma ovárico son haptenizadas dualmente con un grupo dinitrofenilo acoplado a grupos amino, y con un grupo ácido sulfanílico acoplado a cadenaslaterales aromáticas de histidina ytirosina. Las células tumorales haptenizadas dualmente pueden ser utilizadas en preparaciones de vacunas a un dosaje másbajo, y son más eficaces para producir una respuesta inmune favorable.Compositions comprising dual haptenized tumor cells and extracts thereof, methods for preparing the compositions, vaccines comprising such double haptenized tumor cells, and methods for treating cancer with such vaccines. In a specific embodiment, melanoma and ovarian adenocarcinoma cells are haptenized with a dinitrophenyl group coupled to amino groups, and with a sulphanilic acid group coupled to aromatic side chains of histidine and tyrosine. Haptenized tumor cells can be used twice in vaccine preparations at a lower dosage, and are more effective in producing a favorable immune response.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11421998P | 1998-12-30 | 1998-12-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR023925A1 true AR023925A1 (en) | 2002-09-04 |
Family
ID=22354019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990106876A AR023925A1 (en) | 1998-12-30 | 1999-12-30 | EXTRACT OF TUMOR CELLS MODIFIED BY DUAL HAPTENIZATION AND METHODS OF TREATMENT OR PROTECTION FOR CANCER |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR023925A1 (en) |
| AU (1) | AU2487500A (en) |
| WO (1) | WO2000038710A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7297330B2 (en) | 2000-02-04 | 2007-11-20 | Thomas Jefferson University | Low dose haptenized tumor cell and tumor cell extract immunotherapy |
| EP1480660A4 (en) * | 2002-02-01 | 2008-02-20 | Univ Jefferson | Mixed haptenized tumor cells and extracts and methods of treating or screening for cancer |
| AU2003243485A1 (en) * | 2002-06-10 | 2003-12-22 | Avax Technologies Inc. | Cryopreservation of haptenized tumor cells |
| FR3011850B1 (en) * | 2013-10-15 | 2018-04-06 | Cfl Biotech | THERAPEUTIC VACCINE AGAINST CANCER BASED ON IMMUNOGENIC STRESS PROTEINS |
| KR20210076016A (en) * | 2018-09-24 | 2021-06-23 | 바이오백시스 인크. | Bihaptenylated autologous vaccines and uses thereof |
| US20240207381A1 (en) * | 2021-04-27 | 2024-06-27 | Biovaxys, Inc. | Bihaptenized autologous vaccines and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3444684A1 (en) * | 1984-12-07 | 1986-06-19 | Karl Prof. Dr.med. 7302 Ostfildern Theurer | Preparation of conjugated antigens and antibodies (immunoglobulins) directed against them for the purposes of tumour therapy and prophylaxis |
| JPH11507633A (en) * | 1995-06-07 | 1999-07-06 | トーマス・ジェファーソン・ユニバーシティ | Hapten-modified tumor cell extracts and methods for treating or screening for cancer |
-
1999
- 1999-12-29 AU AU24875/00A patent/AU2487500A/en not_active Abandoned
- 1999-12-29 WO PCT/US1999/031297 patent/WO2000038710A2/en active Application Filing
- 1999-12-30 AR ARP990106876A patent/AR023925A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000038710A3 (en) | 2000-11-09 |
| WO2000038710A2 (en) | 2000-07-06 |
| AU2487500A (en) | 2000-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI924069A (en) | TERAPEUTISKT ANVAENDBARA PEPTIDER OCH PEPTIDFRAGMENT | |
| BR0009445A (en) | Use of a lipid-sterolic extract from serenoa repens | |
| NO20015073D0 (en) | vaccinations | |
| AR008799A1 (en) | VACCINE COMPOSITION TO PREVENT OR TREAT MALARIA; USE OF SUCH COMPOSITION TO PREPARE DRUGS AND METHOD FOR SUCH PROPHYLAXIS AND SUCH TREATMENT | |
| DE60206137D1 (en) | HERBAL PLANTS CONTAINING MEDICINAL PRODUCTS | |
| AR005583A1 (en) | A COMPOSITION FOR THE TREATMENT OF CELLULITIS THROUGH TOPIC APPLICATION, A COSMETIC TREATMENT METHOD TO ACHIEVE A SLIMMING EFFECT AND A COSMETIC TREATMENT METHOD TO TIGHTEN THE ADIPOSE ASPECT OF "ORANGE SKIN" OF THE SKIN | |
| ATE328599T1 (en) | ANTITUMORAL AGENTS | |
| MXPA03002576A (en) | METHODS TO TREAT MUSCLE INJURIES. | |
| HUP0302532A2 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
| NO20013701D0 (en) | HER-2 / neu fusion proteins | |
| MXPA03002778A (en) | ANTIANGIOGEN POLYPEPTIDES AND METHODS TO INHIBIT ANGIOGENESIS. | |
| AR023925A1 (en) | EXTRACT OF TUMOR CELLS MODIFIED BY DUAL HAPTENIZATION AND METHODS OF TREATMENT OR PROTECTION FOR CANCER | |
| KR20180084339A (en) | Pharmaceutical composition comprising Korean medicinal herbs for preventing hair loss, melanizing of hair, enhancing hair growth, treating benign prostate hyperplasia and manufacturing method thereof | |
| ES2117029T3 (en) | VACCINE AGAINST AVIAN COCCIDIOSIS. | |
| HUP0204243A2 (en) | Novel helicobacter pylori-binding substances and use thereof | |
| ES2530510T3 (en) | Synthetic peptide constructs for the diagnosis and treatment of periodontitis associated with Porphyromonas gingivalis | |
| ES2185323T3 (en) | USE OF ERYTHROPOIETIN IN THE TREATMENT OF MULTIPLE MYELOMA. | |
| BR0113552A (en) | Liposomes encapsulating anticancer drugs and their use in the treatment of malignant tumors | |
| AR027362A1 (en) | HAPTENIZED TUMOR CELL OF LOW DOSE AND IMMUNOTHERAPY OF TUMOR CELL EXTRACT | |
| BR9815404A (en) | Adjuvant composition to stimulate an efficient immune response to an antigenic substance, vaccine for administration to an animal, process to stimulate an effective immune response in an animal to an antigenic substance, and use of the adjuvant composition. | |
| NO20013787D0 (en) | Soybean extract containing lipids, process for its preparation and pharmaceutical and cosmetic compositions | |
| ES2177535T3 (en) | VACCINES AGAINST INTESTINAL PROTOZES. | |
| WO2003063802A3 (en) | Mixed haptenized tumor cells and extracts and methods of treating or screening for cancer | |
| AR028609A1 (en) | EMPLOYMENT OF VEGETABLE EXTRACTS IN A COSMETIC COMPOSITION TO PROTECT KERATIN FIBERS | |
| GB744438A (en) | Preparation for the treatment of hair |